9 results
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
algorithm for the treatment ... of cancer-associated ... for appropriate dosing ... Anticoagulation #Management ... #Hematology #Oncology
Managing warfarin INR

Warfarin dosage must be individualized according to the patient's response to the drug, and
#management #algorithm ... #pharmacology # ... treatment #medications ... #table #pharmacotherapy ... #warfarin #dosing
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
incidental DVT or PE in cancer ... thrombosis in cancer ... bleeding risk during ... Anticoagulation #Management ... #Hematology #Oncology
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
interactions) Cancer-treatment ... #Chemotherapy #Oncology ... #Hematology #Interactions ... #Table #Pharmacology
Systemic Therapy for Hepatocellular Carcinoma - AGA Clinical Practice Guideline

First Line Treatment for HCC with Preserved
First Line Treatment ... Preserved Liver Function ... #Management #Hepatology ... Gastroenterology #oncology ... #Pharmacology
Lung Abscess - Diagnosis and Management Summary

Lung Abscess Etiology:
 • Necrosis of lung parenchyma by a
Diagnosis and Management ... Lung Abscess Etiology ... Lung Abscess Pathophysiology ... Lung Abscess Management ... foreign body, cancer
Peripartum Cardiomyopathy - Summary
1. Definition
 • Towards the end of pregnancy to 5 months postpartum
Management during ... Management during ... Management during ... studies show no ↓ LV function ... #cardiology #treatment
It is important to recognize Acute Decompensated Heart Failure (ADHF) as more than just simply a
hemodynamics and cardiac function ... then be excreted using ... differential #algorithm #management ... #table #foamed ... icu #clinical #pharmacology
Management of Anthracyclines and HER2 Antagonist Cardiotoxicity
Anthracyclines cause cardiomyopathy:
 ✖ Reduction in left ventricular ejection fraction
Management of Anthracyclines ... ventricular ejection fraction ... ) and initiate treatment ... every 3 months during ... #pharmacology #